# 8-Prenylgenistein Isoflavone in Cheonggukjang Acts as a Novel AMPK Activator Attenuating Hepatic Steatosis by Enhancing the SIRT1-Mediated Pathway

**Authors:** Radha Arulkumar, Hee Jin Jung, Sang Gyun Noh, Hyun Woo Kim, Hae Young Chung

PMC · DOI: 10.3390/ijms25179730 · International Journal of Molecular Sciences · 2024-09-08

## TL;DR

A compound in fermented soybeans activates a key liver protein to reduce fat buildup, offering a potential dietary treatment for liver disease.

## Contribution

8-Prenylgenistein is identified as a novel AMPK activator with superior pharmacokinetics and hepatoprotective effects.

## Key findings

- 8-Prenylgenistein activates AMPK and SIRT1, reducing hepatic steatosis.
- The compound shows better absorption and plasma binding than controls.
- 8-Prenylgenistein promotes fatty acid oxidation in liver cells.

## Abstract

8-Prenylgenistein (8PG), a genistein derivative, is present in fermented soybeans (Glycine max), including cheonggukjang (CGJ), and exhibits osteoprotective, osteogenic, and antiadipogenic properties. However, the hepatoprotective effects of 8PG and its underlying molecular mechanisms remain largely unexplored. Here, we identified the high binding affinity of 8PG with AMP-activated protein kinase (AMPK) and sirtuin 1 (SIRT1), which acts as a potent AMPK activator that counteracts hepatic steatosis. Notably, 8PG exhibited better pharmacokinetics with greater absorption and higher plasma binding than the positive controls for the target proteins. Moreover, 8PG exerted non-carcinogenic activity in rats and significantly increased AMPK phosphorylation. Compound C, an AMPK inhibitor, did not antagonize 8PG-activated AMPK in HepG2 cells. 8PG significantly attenuated palmitate-induced lipid accumulation and enhanced phosphorylated AMPK and its downstream target, acetyl-CoA carboxylase. Further, 8PG activated nuclear SIRT1 at the protein level, which promoted fatty acid oxidation in palmitate-treated HepG2 cells. Overall, 8PG acts as a potent AMPK activator, further attenuating hepatic steatosis via the SIRT1-mediated pathway and providing new avenues for dietary interventions to treat metabolic dysfunction-associated steatotic liver disease (MASLD).

## Linked entities

- **Proteins:** PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1), SIRT1 (sirtuin 1), CAC2 (acetyl Co-enzyme a carboxylase biotin carboxylase subunit)
- **Chemicals:** 8-Prenylgenistein (PubChem CID 5317480), palmitate (PubChem CID 985), Compound C (PubChem CID 11524144)
- **Diseases:** metabolic dysfunction-associated steatotic liver disease (MONDO:0013209)
- **Species:** Glycine max (taxon 3847)

## Full-text entities

- **Genes:** SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562] {aka AMPK, AMPK alpha 1, AMPKa1}
- **Diseases:** carcinogenic (MESH:D011230), Hepatic Steatosis (MESH:D005234), metabolic dysfunction-associated (MESH:D008659), MASLD (MESH:D008107)
- **Species:** Glycine max (soybean, species) [taxon 3847], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Cell lines:** HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11395689/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11395689/full.md

## References

69 references — full list in the complete paper: https://tomesphere.com/paper/PMC11395689/full.md

---
Source: https://tomesphere.com/paper/PMC11395689